Intermittent fasting may benefit antioxidant and inflammatory markers in postmenopausal women with rheumatoid arthritis.
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...
The large cross-sectional study highlights a significant link between elevated inflammatory indices and MAFLD in hypertensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback